<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EF2C6214-52BE-45FA-9F3B-F8ED42DA5586"><gtr:id>EF2C6214-52BE-45FA-9F3B-F8ED42DA5586</gtr:id><gtr:name>Cellular Therapeutics Ltd</gtr:name><gtr:address><gtr:line1>Cellular Therapeutics Ltd,48 Grafton Street</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9XX</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EF2C6214-52BE-45FA-9F3B-F8ED42DA5586" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>EF2C6214-52BE-45FA-9F3B-F8ED42DA5586</gtr:id><gtr:name>Cellular Therapeutics Ltd</gtr:name><gtr:address><gtr:line1>Cellular Therapeutics Ltd,48 Grafton Street</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9XX</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>506224.0</gtr:offerGrant><gtr:projectCost>723177.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/169DB3E0-A45B-44BA-BD70-89C53F178478" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>169DB3E0-A45B-44BA-BD70-89C53F178478</gtr:id><gtr:name>Asymptote Limited</gtr:name><gtr:address><gtr:line1>St John's Innovation Centre
Cowley Road</gtr:line1><gtr:city>Cambridge</gtr:city><gtr:postCode>CB4 0WS</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>311545.0</gtr:offerGrant><gtr:projectCost>623090.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/01B52563-4B82-412B-9A27-D68E1B837256"><gtr:id>01B52563-4B82-412B-9A27-D68E1B837256</gtr:id><gtr:firstName>Ryan</gtr:firstName><gtr:surname>Guest</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=103238"><gtr:id>B38742A8-245E-4448-B687-2CD8DBFFEBEC</gtr:id><gtr:title>genTIL: Generation of a commercially viable Tumour Infiltrating Lymphocyte (TIL) therapy</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Collaborative R&amp;D</gtr:grantCategory><gtr:grantReference>103238</gtr:grantReference><gtr:abstractText>Cancer specific Adoptive T-Cell therapy (ACT) is a form of personalised medicine that harnesses the power of the patient's immune system to direct tumour-specific T-cells to kill cancer cells. The field of adoptive T-cell therapy has approached a point where the pre-clinical promise is now a clinical reality. Since the first report of use of TIL therapy in 1988, it has gone through several generations of improvement with trials using ?Young TILs? unselected T cells and patient preconditioning producing excellent response rates ? around 40% to 50% long term responses and around 10-20% cures. The vast potential of this field of cell therapy has been acknowledged by major pharmaceutical companies who are sponsoring multi-centre clinical trials (e.g. Novartis - CTL019, Adaptimmune/GSK - NY-ESO-1 SPEAR?). There is a market need for a robust reproducible, logistically scalable commercial process suitable for industrialisation of TIL Therapy. However, the wide-spread application of this form of cell therapy on an industrial scale is currently severely limited by the complexity associated with delivering a personalised cancer therapy. This project plans to address the major hurdles in making TIL therapy commercially viable: (i) point of collection and (ii) stabilisation of cellular material and final product.</gtr:abstractText><gtr:fund><gtr:end>2020-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2017-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>817769</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">103238</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>